Could stem cells help women with thin uterine lining get pregnant?
NCT ID NCT06503471
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests whether stem cells from umbilical cords can help women with a thin uterine lining become pregnant. The treatment aims to thicken the lining and reduce scarring, potentially improving pregnancy and live birth rates. The study involves 24 women aged 20-39 who have frozen embryos and a history of uterine adhesions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 24 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Dec 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
20 to 39 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patients aged 20 to 39 years with primary or secondary infertility who have received ivf embryo transfer treatment and have been frozen at least 4 good quality embryos (good quality embryos defined as 7-9C / ⅱ 0 or 4BC or more blastocysts and ≥2 grade ⅰ embryos or 4BC or more blastocysts) 2. Once above 2 times under hysteroscopy surgery adhesions, uterine cavity form has returned to normal, with normal menstrual cycle or at least a cycle high-dose estrogen replacement therapy for more than 12 days (\> 4 mg/day, maximum dose of more than 8 mg/day), after treatment the biggest endometrial thickness of 7 mm or less or upper middle period of endometrial thickness of 7 mm or less on average; Or received assisted reproductive therapy, after at least 4mg/ day of estrogen, colony stimulating factor, aspirin, sildenafil and other drugs, unknown maximum endometrial thickness ≤7mm or average endometrial thickness ≤7mm in middle and upper segment; The maximum endometrial thickness in luteal phase was less than 6mm 3. 18kg/m2\< body mass index (BMI) \<24 kg/m2 4. Voluntarily participate and sign the informed consent 5. Negative coV-19 nucleic acid test Exclusion Criteria: 1. Uncured sexually transmitted diseases 2. Participate in other clinical investigators within 3 months 3. Serum pregnancy tested positive 4. Coagulopathy or other diseases of the blood system 5. Severe heart disease, unstable angina attack, cardiac insufficiency of grade III or above, acute myocardial infarction and/or old myocardial infarction, hypertension was diagnosed according to the guidelines for prevention and treatment of hypertension in China (2010 edition) 6. Patients with active genital tuberculosis 7. Patients with immune system disorders 8. Diseases related to pregnancy outcome (any) : Untreated hydrosalpinx, untreated uterine polyp, untreated uterine infection, phase III \~ Ⅳ endometriosis and adenomyosis of the uterus, ovarian cyst \> 4 cm, uterine fibroids \> 2 cm in diameter, multiple muscle intramural myoma, and submucosal fibroids, cesarean section incision site benign tumor prognosis, basin celiac \> 4 cm, pituitary tumors and malignant tissues and organs tumors 9. Abnormal uterine bleeding 10. Severe liver and kidney function injury, namely, blood alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were 2.5 times higher than the upper limit of normal value, and blood creatinine (Cr) and urea nitrogen (BUN) were 2 times higher than the upper limit of normal value 11. The researcher considers that she is not suitable for this study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Infertility, female are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Changsha Reproductive Medicine Hospital (Changsha Ning 'er Maternity Hospital)
Changsha, Hunan, 410217, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Innovation for Women's health: the integration of artificial intelligence in the diagnostic ultrasound assessment of reproductive medicine
- One shot instead of many: a simpler path to IVF egg retrieval?
- Can sex boost the odds of IVF success?
- IVF Needle-Free? oral pill tested as injection alternative
- Obesity may blunt the Brain's ovulation signal, study hints
- Could a fibroid drug help women with adenomyosis finally achieve a live birth?